Personalized mRNA Vaccine Plus Keytruda Boosts Melanoma Survival
Researchers reported on June 1, 2026, that a personalized mRNA vaccine combined with the immunotherapy drug pembrolizumab (Keytruda) sharply boosted five-year survival after surgery for high-risk melanoma.[1]
In a randomized trial of 157 patients in the U.S. and Australia whose tumors had been removed, 68.8% on the vaccine-plus-Keytruda were cancer-free at five years versus 49.1% with Keytruda alone.[1] Overall survival at five years was 92% with the combination versus 71% with Keytruda alone.[1]
Each mRNA vaccine was customized to the individual patient's tumor antigens, representing a personalized immunotherapy approach.[1] The results were published June 1, 2026, in the Journal of Clinical Oncology and presented the same day at the American Society of Clinical Oncology conference.[1]
If larger studies confirm these findings, the approach could change adjuvant treatment for patients at high risk of melanoma recurrence by lowering both relapse and death.
Show source details & analysis (1 source)
📌 Key Facts
- The trial enrolled 157 melanoma patients in the U.S. and Australia who had tumors surgically removed and were at high risk of recurrence.
- After five years, 68.8% of patients on the personalized mRNA vaccine plus Keytruda were cancer-free, versus 49.1% on Keytruda alone.
- Overall survival at five years was 92% with the combination therapy compared with 71% with Keytruda alone.
- Results were published June 1, 2026, in the Journal of Clinical Oncology and presented the same day at the American Society of Clinical Oncology conference.
- Each mRNA vaccine was customized to the individual patient's tumor antigens, representing a personalized immunotherapy approach.
📰 Source Timeline (1)
Follow how coverage of this story developed over time